Stenotrophomonas maltophilia infections in a general hospital: Patient characteristics, antimicrobial susceptibility, and treatment outcome

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Samonis, George ^a   Karageorgopoulos, Drosos E ^b,c   Maraki, Sofia ^a   Levis, Panagiotis ^b   Dimopoulou, Dimitra ^a   Spernovasilis, Nikolaos A ^a   Kofteridis, Diamantis P ^a   Falagas, Matthew E ^b,d,e  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^c Hellenic Center for Disease Control and Prevention   (Greece)

^d HENRY DUNANT HOSPITAL   (Greece)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; NETILMICIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TIGECYCLINE; TIMENTIN; TOBRAMYCIN; TRIMETHOPRIM;

ABDOMINAL INFECTION; ADULT; AGAR DILUTION; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BLOODSTREAM INFECTION; CAUSE OF DEATH; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; EYE INFECTION; FEMALE; GENERAL HOSPITAL; GRAM NEGATIVE INFECTION; GREECE; HOSPITAL DEPARTMENT; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MEDICAL WARD; MONOTHERAPY; MORTALITY; NONHUMAN; ONCOLOGY WARD; OUTCOME ASSESSMENT; PROGNOSIS; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; SKIN INFECTION; SOFT TISSUE INFECTION; STENOTROPHOMONAS MALTOPHILIA; STENOTROPHOMONAS MALTOPHILIA INFECTION; SURGICAL WARD; URINARY TRACT INFECTION; BACTERIAL COUNT; CROSS INFECTION; MULTIDRUG RESISTANCE; NONPARAMETRIC TEST; STATISTICAL MODEL; TREATMENT OUTCOME;

STENOTROPHOMONAS MALTOPHILIA;

AGED; CIPROFLOXACIN; COLISTIN; COLONY COUNT, MICROBIAL; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GREECE; HUMANS; LOGISTIC MODELS; MALE; NETILMICIN; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; STENOTROPHOMONAS MALTOPHILIA; TREATMENT OUTCOME; TRIMETHOPRIM;

EID: 84862062038     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037375     Document Type: Article

References (38)

1. Denton M, Kerr KG, (1998) Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 11: 57-80.
2. Brooke JS, (2012) Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev 25: 2-41.
3. VanCouwenberghe CJ, Farver TB, Cohen SH, (1997) Risk factors associated with isolation of Stenotrophomonas (Xanthomonas) maltophilia in clinical specimens. Infect Control Hosp Epidemiol 18: 316-321.
4. Penzak SR, Abate BJ, (1997) Stenotrophomonas (Xanthomonas) maltophilia: a multidrug-resistant nosocomial pathogen. Pharmacotherapy 17: 293-301.
5. Valdezate S, Vindel A, Martín-Dávila P, Del Saz BS, Baquero F, et al. (2004) High genetic diversity among Stenotrophomonas maltophilia strains despite their originating at a single hospital. J Clin Microbiol 42: 693-699.
6. San Gabriel P, Zhou J, Tabibi S, Chen Y, Trauzzi M, et al. (2004) Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 48: 168-171.
7. Looney WJ, Narita M, Muhlemann K, (2009) Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis 9: 312-323.
8. Safdar A, Rolston KV, (2007) Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis 45: 1602-1609.
9. Vila J, Marco F, (2002) [Interpretative reading of the non-fermenting gram-negative bacilli antibiogram]. Enferm Infecc Microbiol Clin 20: 304-310.
10. Garrison MW, Anderson DE, Campbell DM, Carroll KC, Malone CL, et al. (1996) Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model. Antimicrob Agents Chemother 40: 2859-2864.
11. Horan TC, Andrus M, Dudeck MA, (2008) CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36: 309-332.
12. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement CLSI Document M100-S20. Wayne, PA, USA 2010.
13. Leclercq R, Canton R, Brown DF, Giske CG, Heisig P, et al. (2011) EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect.
14. del Toro MD, Rodriguez-Bano J, Herrero M, Rivero A, Garcia-Ordonez MA, et al. (2002) Clinical epidemiology of Stenotrophomonas maltophilia colonization and infection: a multicenter study. Medicine (Baltimore) 81: 228-239.
15. Laing FP, Ramotar K, Read RR, Alfieri N, Kureishi A, et al. (1995) Molecular epidemiology of Xanthomonas maltophilia colonization and infection in the hospital environment. J Clin Microbiol 33: 513-518.
16. Gülmez D, Çakar A, Şener B, Karakaya J, Hasçelik G, (2010) Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing. J Infect Chemother 16: 322-328.
17. Nicodemo AC, Paez JI, (2007) Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis 26: 229-237.
18. Crossman LC, Gould VC, Dow JM, Vernikos GS, Okazaki A, et al. (2008) The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants. Genome Biol 9: R74.
19. Toleman MA, Bennett PM, Bennett DM, Jones RN, Walsh TR, (2007) Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes. Emerg Infect Dis 13: 559-565.
20. Hu LF, Chang X, Ye Y, Wang ZX, Shao YB, et al. (2011) Stenotrophomonas maltophilia resistance to trimethoprim/sulfamethoxazole mediated by acquisition of sul and dfrA genes in a plasmid-mediated class 1 integron. Int J Antimicrob Agents 37: 230-234.
21. Falagas ME, Valkimadi PE, Huang YT, Matthaiou DK, Hsueh PR, (2008) Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J Antimicrob Chemother 62: 889-894.
22. Valdezate S, Vindel A, Loza E, Baquero F, Cantón R, (2001) Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains. Antimicrob Agents Chemother 45: 1581-1584.
23. Vartivarian S, Anaissie E, Bodey G, Sprigg H, Rolston K, (1994) A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob Agents Chemother 38: 624-627.
24. Valdezate S, Vindel A, Saez-Nieto JA, Baquero F, Canton R, (2005) Preservation of topoisomerase genetic sequences during in vivo and in vitro development of high-level resistance to ciprofloxacin in isogenic Stenotrophomonas maltophilia strains. J Antimicrob Chemother 56: 220-223.
25. Lecso-Bornet M, Pierre J, Sarkis-Karam D, Lubera S, Bergogne-Berezin E, (1992) Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro. Antimicrob Agents Chemother 36: 669-671.
26. Farrell DJ, Sader HS, Jones RN, (2010) Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother 54: 2735-2737.
27. Gales AC, Jones RN, Sader HS, (2006) Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect 12: 315-321.
28. Nicodemo AC, Araujo MR, Ruiz AS, Gales AC, (2004) In vitro susceptibility of Stenotrophomonas maltophilia isolates: comparison of disc diffusion, Etest and agar dilution methods. J Antimicrob Chemother 53: 604-608.
29. Gales AC, Reis AO, Jones RN, (2001) Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 39: 183-190.
30. Betriu C, Rodríguez-Avial I, Sánchez BA, Gómez M, Picazo JJ, (2002) Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia. J Antimicrob Chemother 50: 758-759.
31. Traub WH, Leonhard B, Bauer D, (1998) Antibiotic susceptibility of Stenotrophomonas (Xanthomonas) maltophilia: comparative (NCCLS criteria) evaluation of antimicrobial drugs with the agar dilution and the agar disk diffusion (Bauer-Kirby) tests. Chemotherapy 44: 164-173.
32. Blanquer D, De Otero J, Padilla E, Gomez F, Mayol A, et al. (2008) Tigecycline for treatment of nosocomial-acquired pneumonia possibly caused by multi-drug resistant strains of Stenotrophomonas maltophilia. J Chemother 20: 761-763.
33. Lambert T, Ploy MC, Denis F, Courvalin P, (1999) Characterization of the chromosomal aac(6′)-Iz gene of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 43: 2366-2371.
34. Li XZ, Zhang L, McKay GA, Poole K, (2003) Role of the acetyltransferase AAC(6′)-Iz modifying enzyme in aminoglycoside resistance in Stenotrophomonas maltophilia. J Antimicrob Chemother 51: 803-811.
35. Falagas ME, Kastoris AC, Vouloumanou EK, Rafailidis PI, Kapaskelis AM, et al. (2009) Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature. Future Microbiol 4: 1103-1109.
36. Kwa AL, Low JG, Lim TP, Leow PC, Kurup A, et al. (2008) Independent predictors for mortality in patients with positive Stenotrophomonas maltophilia cultures. Ann Acad Med Singapore 37: 826-830.
37. Paez JI, Costa SF, (2008) Risk factors associated with mortality of infections caused by Stenotrophomonas maltophilia: a systematic review. J Hosp Infect 70: 101-108.
38. Araoka H, Baba M, Yoneyama A, (2010) Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996-2009. Eur J Clin Microbiol Infect Dis 29: 605-608.